FDA withholds approval for REGENXBIO gene therapy for Hunter syndrome

On February 7, 2026 the FDA issued a Complete Response Letter for REGENXBIO's BLA for RGX-121 (clemidsogene lanparvovec) for MPS II, reversing earlier accelerated-approval acceptance from May 2025 and citing uncertainties in defining the neuronopathic population, comparability of the external natural-history control, and the validity of CSF HS D2S6 as a surrogate endpoint. The FDA noted it agreed to the study protocol in principle; REGENXBIO plans to request a Type A meeting, provide additional analyses and longer-term clinical data, and pursue a BLA resubmission, though proposed paths (new study, additional patients or untreated controls) are operationally challenging in this ultra-rare indication. The decision is a material negative catalyst for the company’s valuation and near-term approval prospects, while the firm retains an unused $300 million S-3 shelf and will seek regulatory engagement to clarify a development path.

Analysis

Market structure: The CRL is a company-specific negative shock that removes near-term revenue optionality for RGNX’s RGX-121 and increases investor willingness to rotate capital into other gene-therapy/rare-disease names (e.g., ARCT, REPL, BCYC) and large-cap pharm (ABBV, NVS). Expect RGNX to underperform small-cap biotech indices by 15–40% volatility in the next 30–90 days while implied vol on RGNX options spikes 30–80%. Limited alternative suppliers/treatments for neuronopathic MPS II means clinical comparators and recruitment dynamics—not pricing—are the constrained resource.

Risk assessment: Tail risks include a requirement for a new randomized study (12–36 months) or inability to recruit untreated controls, potential partner withdrawal, and equity dilution via the $300M S-3 (realized if cash burn forces a raise), each capable of cutting equity value by 30–70%. Immediate (days): headline-driven trading and IV; short-term (30–180 days): Type A meeting outcome and clarity on surrogate endpoint acceptance; long-term (year+): potential resubmission timeline and commercial launch assumptions if approved. Hidden dependencies: regulator acceptance of external natural-history controls and pediatric enrollment rates; payers will demand robust clinical endpoints before pricing.

Trade implications: Direct play—establish a tactical bearish position on RGNX: 2–4% portfolio short via 3-month put spreads (buy 25-delta, sell 10-delta) targeting 30–50% upside if shares fall 20–40%; cut if positive Type A agreement is announced. Pair trade—long 2–3% notional ARCT or REPL vs short equal notional RGNX to capture relative-rotation; hedge sector delta with a small ABBV/NVS long (2%) to lower idiosyncratic risk. Reduce small-cap gene-therapy exposure by ~25% over 2 weeks; redeploy into large-cap pharm for yield/defense.

Contrarian angles: The market may be over-discounting RGX-121—FDA previously accepted the BLA under accelerated approval and agreed the protocol “in principle,” so a negotiated path (additional follow-up vs limited new enrollments) is plausible within 6–12 months. Historical gene-therapy CRLs often led to delays not deaths of programs; if REGENXBIO secures regulator alignment on CSF HS D2S6 or comparator matching at the Type A meeting (expected scheduling within 30 days), the stock could retrace 30–60% of the initial drop. Watch for S-3 takedowns and partner statements as early signals of dilution or support.

Key Decisions for Investors

• Establish a tactical bearish position in RGNX equal to 2–4% of portfolio via 3-month put spreads (buy 25-delta, sell 10-delta) sized to risk no more than 1% portfolio loss; take profits if RGNX falls 25–40% or close within 5 trading days of a clear positive Type A meeting outcome.
• Initiate a pair trade: long 2–3% notional ARCT (or REPL/BCYC) and short equal notional RGNX to capture sector rotation; rebalance after 30–60 days or upon publication of Type A meeting minutes.
• Reduce aggregate small-cap gene-therapy exposure by ~25% over the next 2 weeks and redeploy 2–4% into large-cap pharma (ABBV, NVS) for defensive carry until regulatory clarity (target horizon 3–6 months).
• Monitor three specific triggers within 30–60 days: (1) Type A meeting scheduling and minutes (if FDA concedes comparator/surrogate path, cover shorts within 5 days); (2) any S-3 takedown or equity raise (if >$50M executed, widen shorts); (3) partner statements from Nippon Shinyaku/AbbVie (if either reduces commitment, increase short exposure).